Second Malignancies in Total Therapy 3 Trials for Newly Diagnosed Multiple Myeloma: Influence of Lenalidomide Versus Thalidomide in Maintenance Phases

被引：0
|
作者：
Usmani, Saad [1 ]
Sexton, Rachael [2 ]
Hoering, Antje [2 ]
Heuck, Christoph [1 ]
Nair, Bijay [1 ]
Waheed, Sarah [1 ]
Alsayed, Yazan [1 ]
Petty, Nathan M. [1 ]
Crowley, John [2 ]
Barlogie, Bart [1 ]
机构：
[1] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA
[2] Canc Res & Biostat, Res & Biostat, Seattle, WA USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：375 / 375
页数：1
相关论文
共 50 条
  • [31] Lenalidomide or Thalidomide for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma? An Overview of Systematic Reviews
    Visacri, Manlia Berlofa
    Ribeiro, Mayra Carvalho
    Komoda, Denis Satoshi
    Duarte, Bruno Kosa Lino
    Correa, Carlos Roberto Silveira
    Maia, Flavia de Oliveira Motta
    Alves, Daniela Fernanda dos Santos
    VALUE IN HEALTH REGIONAL ISSUES, 2024, 43
  • [32] Phase II Trial of Syncopated Thalidomide, Lenalidomide, and Weekly Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Tufail, Madiha
    Siegel, David S.
    McBride, Laura
    Bilotti, Elizabeth
    Bello, Erica
    Anand, Palka
    Olivo, Karly
    Bendarz, Urszula
    McNeill, Ann
    Vesole, David H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (03): : 186 - 190
  • [33] Total therapy with tandem transplants for newly diagnosed multiple myeloma
    Barlogie, B
    Jagannath, S
    Desikan, KR
    Mattox, S
    Vesole, D
    Siegel, D
    Tricot, G
    Munshi, N
    Fassas, A
    Singhal, S
    Mehta, J
    Anaissie, E
    Dhodapkar, D
    Naucke, S
    Cromer, J
    Sawyer, J
    Epstein, J
    Spoon, D
    Ayers, D
    Cheson, B
    Crowley, J
    BLOOD, 1999, 93 (01) : 55 - 65
  • [34] A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma
    Khan, Meaghan L.
    Reeder, Craig B.
    Kumar, Shaji K.
    Lacy, Marthy Q.
    Reece, Donna E.
    Dispenzieri, Angela
    Gertz, Morie A.
    Greipp, Phillip
    Hayman, Suzanne
    Zeldenhurst, Steven
    Dingli, David
    Lust, John
    Russell, Stephen
    Laumann, Kristina M.
    Mikhael, Joseph R.
    Bergsagel, P. Leif
    Fonseca, Rafael
    Rajkumar, S. Vincent
    Stewart, A. Keith
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (03) : 326 - 333
  • [35] A COMBINATION THERAPY WITH BORTEZOMIB (BOR) AND THALIDOMIDE IN NEWLY DIAGNOSED MYELOMA PATIENTS IS ASSOCIATED WITH A LOW INCIDENCE OF SECOND PRIMARY MALIGNANCIES (SPMS)
    Brioli, A.
    Galli, M.
    Tacchetti, P.
    Crippa, C.
    Spadano, T.
    Pezzi, A.
    Pescosta, N.
    Baldini, L.
    Zannetti, B. A.
    Terragna, C.
    Cellini, C.
    Rocchi, S.
    Falcone, A.
    Nozzoli, C.
    Marzocchi, G.
    Dico, F.
    Masini, L.
    Palumbo, A.
    Cavo, M.
    HAEMATOLOGICA, 2014, 99 : 373 - 373
  • [36] Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
    Liang, Dong
    Bai, Shenrui
    Feng, Demei
    Chen, Guanjun
    Liang, Yang
    Wang, Hua
    BMC CANCER, 2024, 24 (01)
  • [37] MajesTEC-4: Phase 3 trial of Teclistamab plus Lenalidomide versus Lenalidomide in patients with newly diagnosed multiple myeloma
    Cook, Gordon
    Zamagni, Elena
    Boccadoro, Mario
    Spencer, Andrew
    Delforge, Michel
    Reece, Donna
    Szabo, Agoston Gyula
    Einsele, Hermann
    Terpos, Evangelos
    Schjesvold, Fredrik
    Bila, Jelena
    Driessen, Christoph
    Beksac, Meral
    Rodriguez, Cesar
    Pei, Lixia
    Shi, Yingqi
    Sakabedoyan, Caline
    Jasielec, Jagaoda
    Amin, Himal
    Kobos, Rachel
    Sonneveld, Pieter
    Van De Donk, Niels
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 57 - 57
  • [38] FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
    Pulte, Elizabeth Dianne
    Dmytrijuk, Andrew
    Nie, Lei
    Goldberg, Kirsten B.
    McKee, Amy E.
    Farrell, Ann T.
    Pazdur, Richard
    ONCOLOGIST, 2018, 23 (06): : 734 - 739
  • [39] Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma
    Brioli, Annamaria
    Kaiser, Martin F.
    Pawlyn, Charlotte
    Wu, Ping
    Gregory, Walter M.
    Owen, Roger
    Ross, Fiona M.
    Jackson, Graham H.
    Cavo, Michele
    Davies, Faith E.
    Morgan, Gareth J.
    LEUKEMIA & LYMPHOMA, 2013, 54 (09) : 1975 - 1981
  • [40] Quadruplets, Maintenance, and More: The Future of Therapy for Newly Diagnosed Multiple Myeloma
    Krishnan, Amrita
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S159 - S160
12345